Nerve Damage Treatment with MIBRAR®

Nerve tissue damage is traditionally considered among the most difficult conditions to treat. Nerve cells have limited regenerative capacity, and conventional therapies often aim only to slow disease progression. MIBRAR® technology opens fundamentally new possibilities — stimulating nerve tissue regeneration using autologous stem cells and growth factors.

Indications — Nerves and Sensory Organs

The MIBRAR® method is used for the following nervous system and sensory organ pathologies:

• Optic nerve damage — traumatic, ischemic, glaucomatous
• Eye trauma — post-traumatic changes to the retina and optic nerve
• Diabetic retinopathy — damage to retinal vessels and nerve structures
• Macular degeneration — age-related degeneration of the central retinal zone
• Trigeminal neuralgia — intense facial pain
• Facial nerve damage — paresis, Bell's palsy
• Hearing loss / deafness — sensorineural hearing loss
• Peripheral neuropathies — limb nerve damage

Why Nerves Regenerate Poorly

Nerve tissue differs from other body tissues in its extremely limited self-repair potential. Neurons are highly specialized cells that virtually do not divide in the adult body. When a nerve fiber is damaged, its distal part degenerates (Wallerian degeneration), and axon regeneration proceeds very slowly — approximately 1 mm per day.

Additional factors hindering recovery:

• Scar tissue formation in the damage zone
• Impaired blood supply to nerve tissue
• Inflammatory processes
• Lack of neurotrophic factors

MIBRAR® technology addresses precisely these problems — delivering a concentrate of growth factors and stem cells to the affected area, capable of stimulating regeneration.

MIBRAR® Technology for Nerves

MIBRAR® (Micro-Invasive Biological Regenerative Autologous Reconstruction) — Prof. Babayan's method that allows delivery of high concentrations of regenerative factors directly to damaged nerve tissue.

The method's philosophy: "No cut, only a puncture!" A surgical incision creates a competing wound that diverts the body's regenerative resources. Minimally invasive access directs all recovery potential to the target pathology.

ARK® — autologous regenerative concentrate — is used for treatment:

• AHF® (CGF method) — plasma with growth factors, anti-inflammatory factors, and CD34+ stem cells from venous blood
• ALF® (Lipogems® method) — pluripotent mesenchymal stem cells from adipose tissue

The concentrate is precisely injected into the pathology zone under navigation system control (Cyber Navi Hand™ and Sono Control Arm™) with 0.1 mm accuracy. Growth factors stimulate axon regeneration, and mesenchymal stem cells can differentiate into glial cells supporting nerve tissue.

Optic Nerve and Eye Diseases

Optic nerve and retinal diseases are among the most promising applications of MIBRAR®. In glaucomatous, ischemic, or traumatic optic nerve damage, retinal ganglion cells and their axons die.

Diabetic retinopathy — a diabetes complication affecting retinal vessels. This leads to ischemia, macular edema, and pathological vessel proliferation. MIBRAR® affects multiple pathogenesis links: growth factors improve microcirculation, reduce inflammation, and stimulate restoration of retinal nerve structures.

Macular degeneration — an age-related disease affecting the central retinal zone (macula). The patient loses central vision while preserving peripheral vision. ARK® is injected into the retrobulbar space, providing trophic support to photoreceptors and pigment epithelium.

Trigeminal and Facial Nerves

Trigeminal neuralgia — one of the most excruciating pain disorders. Patients describe the pain as an "electric shock" to the face. The cause is often nerve compression by a vessel or demyelination. MIBRAR® allows direct nerve treatment: growth factors promote remyelination, reduce inflammation, and neuropathic pain.

Facial nerve damage (paresis, Bell's palsy) leads to facial asymmetry, impaired mimicry, and problems closing the eye. ARK® injection near the facial nerve exit from the skull (stylomastoid foramen) stimulates regeneration of damaged fibers and accelerates functional recovery.

Auditory Nerve and Hearing Loss

Sensorineural hearing loss — hearing loss caused by damage to the inner ear or auditory nerve. Standard treatment (hearing aids, cochlear implants) compensates for the deficit but does not restore damaged structures.

MIBRAR® opens new prospects: ARK® injection in the mastoid region provides access to structures of the inner ear. Growth factors and stem cells can stimulate restoration of damaged hair cells and auditory nerve fibers.

Peripheral Nerves

Peripheral nerve damage (neuropathies) can result from trauma, compression, metabolic disorders (diabetes), or autoimmune processes. Symptoms include pain, numbness, weakness, and muscle atrophy.

MIBRAR® allows precise injection of ARK® along the damaged nerve under ultrasound guidance. This stimulates axon regeneration, improves blood supply to the nerve, and reduces scar tissue formation.

Results and Prognosis

Results of MIBRAR® treatment for nerve damage depend on the type and duration of the pathology. Typical dynamics:

• 20% improvement from day 1 — reduction of inflammation and pain
• 35% by week 2 — beginning of functional restoration
• 25% by week 4 — continued improvement
• 15% by week 6 — consolidation of result
• Up to 85% total improvement — maximum achievable result

It's important to understand: nerve regeneration is a slow process. Full effect assessment requires 3-6 months. In some cases, repeated procedures are recommended to enhance the effect.